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Previous studies showed that hydrolysates of 𝛽-lactoglobulin (BLG) prepared using gastrointestinal proteases strongly inhibit
dipeptidyl peptidase-IV (DPP-IV) activity in vitro. In this study, we developed a BLG-secreting Lactococcus lactis strain as a delivery
vehicle and in situ expression system. Interestingly, trypsin-digested recombinant BLG from L. lactis inhibited DPP-IV activity,
suggesting that BLG-secreting L. lactismay be useful in the treatment of type 2 diabetes mellitus.
1. Introduction
𝛽-Lactoglobulin (BLG) is the major whey protein in the milk
of cows and other ruminants, as well as some nonruminants,
but it is not contained in human breast milk [1]. BLG is
widely recognized as a high-functional protein [2]. Previous
studies have consistently demonstrated that hydrolysates of
BLGprepared using gastrointestinal proteases such as trypsin
or pepsin have an inhibitory effect on dipeptidyl peptidase-
IV (DPP-IV, also known as CD26) activity [3–8]. DPP-IV
is a serine protease that is ubiquitously expressed in vivo,
and its endogenous physiological substrates are incretins [9].
The incretins, primarily glucose-dependent insulinotropic
polypeptide and glucagon-like peptide-1, are gastrointestinal
hormones released from intestinal L and K cells, respectively.
Incretins drive insulin secretion in pancreatic 𝛽 cells and
suppress pancreatic glucagon production [10, 11]. Thus, DPP-
IV inhibitors, such as vildagliptin, saxagliptin, sitagliptin,
alogliptin, and linagliptin, are used in the management of
type 2 diabetes mellitus (T2D).
We hypothesized that intestinal mucosa-targeted oral
delivery of BLG might be a useful strategy for managing
T2D. Generally recognized as safe (i.e., GRAS), genetically
modified lactic acid bacteria (LAB) have recently emerged
as vehicles for the efficient delivery of therapeutic proteins
and as stable producers of these proteins in situ [12]. In this
study, we engineered a Lactococcus (L.) lactis strain to secrete
BLG and validated the DPP-IV-inhibiting activity of trypsin-
digested recombinant BLG (rBLG).
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2. Materials and Methods
2.1. Bacterial Strains and Growth Conditions. L. lactis
NZ9000 (NZ9000; MoBiTec, Goettingen, Germany), derived
from L. lactis subsp. cremoris MG1363 (MG1363), which
harbors the regulatory genes nisR and nisK integrated into
the pepN gene, was used as a host strain. NZ9000 was
grown at 30∘C without shaking in M17 broth (OXOID,
Hampshire, UK) supplemented with 0.5% glucose (GM17).
rNZ9000 strains were grown in GM17 with 20𝜇g/mL of
chloramphenicol.
2.2. Construction of rNZ9000 Strains. To create the secre-
tion vector for L. lactis, the sequence of usp45, the lac-
tococcal signal peptide, was inserted into pNZ8148#2:CYT
[13] between the nisin-inducible promoter (𝑃nis) and 6x
His-tag sequences; the resulting plasmid was designated
pNZ8148#2:SEC (Figure 1(a)).The pNZ8148#2:CYT vector is
a modified form of the L. lactis expression vector pNZ8148
(MoBiTec).
The gene encoding BLG (accession number: EU883598)
was synthesized and subcloned into pGEM-T easy opti-
mized for MG1363 codon-usage by Eurofins Genomics
(Tokyo, Japan). The sequence of the BLG gene was subse-
quently cloned between the KpnI and HindIII restriction
sites in pNZ8148#2:SEC, generating pNZ8148#2:SEC-BLG
(Figure 1(b)).
The pNZ8148#2:SEC-BLG vector was introduced into
NZ9000 by electroporation using a Gene Pulser Xcell elec-
troporation system (Bio-RadLaboratories Inc., CA,USA) fol-
lowing the manufacturer’s instructions.The resulting recom-
binant strainwas designatedNZ9000:SEC-BLG.NZ9000was
also electroporated with the empty plasmid pNZ8148#2:SEC
to generate an NZ9000 vector control strain (NZ9000:SEC-
VC).
2.3. Small-Scale Expression of rBLG. A 1.9mL aliquot of fresh
medium was inoculated with 0.1mL of an overnight culture
and incubated at 30∘C without shaking. When the turbidity
of the culture reached an optical density at 600 nm (OD
600
)
of 0.4 (1.5 to 2 h later), various concentrations of nisin were
added and the culture was incubated for an additional 3 to
4 h. The OD
600
of the culture was measured at the end of the
incubation period.
Cells were isolated from the nisin-induced culture via
centrifugation for 1min at 8,000×g and 4∘C. Protein extracts
were prepared from the cells using previously described
methods [14]. Proteins remaining in the supernatant were
isolated and concentrated using trichloroacetic acid (TCA)
precipitation. Briefly, 300𝜇L of cold 100% (w/v) TCA solution
was added to 1.5mL of supernatant and the mixture was
placed on ice for 3 h. The resulting precipitates were pelleted
by centrifugation at 20,400×g and 4∘C.To completely remove
the TCA, the protein pellet was washed twice with ice-cold
acetone. The resulting pellet was dried at 55∘C and then
dissolved in a small amount of TE buffer (10mM Tris-HCl
(pH 8.0), 1mM EDTA). An equal volume of 2x sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) sample buffer was added to each sample. The cell and
supernatant fractions were boiled for 5min or placed at room
temperature overnight, respectively, and then subjected to
SDS-PAGE (15% (v/v) polyacrylamide).
Electrophoresed proteins were transferred from the gel
onto a Hybond-P polyvinylidene difluoride membrane (GE
Healthcare, Buckinghamshire, UK). Western blotting was
performed with primary antibody (Ab) against the 6x His-
tag (1:1,000; BioLegend Inc., San Diego, CA, USA), followed
by incubation with a horseradish peroxidase-conjugated
secondary Ab (1:5,000; Sigma, St. Louis, MO, USA). The
resulting blots were visualized using an ECLWestern Blotting
Analysis System (GEHealthcare). Signals were detected using
a lumino image analyzer (ImageQuant LAS 4000 mini, GE
Healthcare) and analyzed using ImageQuant TL software (GE
Healthcare).
2.4. Purification of rBLG. Expression of rBLG in
NZ9000:SEC-BLG was induced in a 4 L large-scale culture
according to the above-mentioned methods. Following
induction of rBLG expression, cells were harvested by
centrifugation for 20min at 3,000×g and 4∘C. The cell pellet
was washed twice with phosphate buffer (50mM NaH
2
PO
4
,
300mM NaCl, pH 8.0) and resuspended with 80mL of
phosphate buffer containing EDTA-free proteinase inhibitor
cocktail (Roche Diagnostics, Indianapolis, IN, USA). To
disrupt the cells, the bacterial suspension was homogenized
with 0.2mm glass beads for 3min using a beads beater
(Beads Crasher 𝜇T-12, Taitec, Saitama, Japan) operating at
3,200 rpm. Soluble proteins released from the bacterial cells
were collected by centrifugation for 15min at 20,400×g and
4∘C.
The rBLG was purified from the prepared lysate using
a HisTrap HP column (1mL, precharged with Ni2+; GE
Healthcare) under native conditions. The phosphate buffer-
equilibrated column was filled with the prepared lysate and
then the flow-through was collected. Next, nonadsorbed
proteins were eluted using wash buffer (phosphate buffer
containing 20mM imidazole). Adsorbed proteinswere eluted
with elution buffers (phosphate buffer containing 31, 63, 125,
250, or 500mM imidazole). The prepurification crude lysate
and the flow-through and eluted fractions were analyzed
by Western blotting with an anti-6x His-tag Ab. Eluted
fractions were dialyzed against Tris-buffered saline (TBS;
50mM Tris-HCl (pH 8.0), 138mM NaCl, and 2.7mM KCl)
and frozen at −80∘C until use. The protein concentration
of the dialyzed samples was measured with a BCA Protein
Assay Kit (Thermo Scientific, Rockford, IL, USA) before the
samples were frozen.
2.5. Trypsin Digestion of BLG. Commercial BLG (cBLG;
Sigma) was dissolved in TBS at a concentration of 1mg/mL.
Purified TBS-dialyzed rBLG was diluted to 50 𝜇g/mL with
TBS. Trypsin (from porcine pancreas, Wako Pure Chemical
Industries Ltd., Osaka, Japan) was added at an enzyme to
substrate ratio of 1 : 20 (w/w) and the mixture was incubated
at 37∘C for 24 h with gentle agitation. Digestion was stopped
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Figure 1:Maps of vectors used in this study. (a) Schematic representation of the secretion vector, pNZ8148#2:SEC.TheDNAsequence between
the RBS and the stop codon is presented in the rectangle. (b) The codon-optimized BLG gene (537 bp) was cloned into pNZ8148#2:SEC
(above) between the KpnI and HindIII restriction enzyme recognition sites, and the resulting plasmid was designated pNZ8148#2:SEC-BLG
(below). 𝑃nis: nisin-inducible promoter; RBS: ribosome binding site; SP𝑢𝑠𝑝45: sequence of the signal peptide of the usp45 gene product; His-
tag: 6x histidine-tag; FXa: factor Xa recognition site; MCS: multiple cloning site; T: terminator; rep: replication gene; cm: chloramphenicol
acetyltransferase gene; BLG: 𝛽-lactoglobulin.
by heating the sample at 90∘C for 5min.The reactionmixture
was kept frozen at −80∘C until used in experiments.
2.6. Analysis of DPP-IV Inhibition. The DPP-IV inhibition
assay was performed using a DPP-IV Drug Discovery Kit
according to the manufacturer’s instructions. Fluorescence
resulting from degradation of substrate (H-Gly-Pro-AMC)
by DPP-IV was detected using a Fluoroskan Ascent FL
Microplate Fluorometer (Thermo Scientific) at excitation
and emission wavelengths of 355 and 460 nm, respectively.
Data are expressed as DPP-IV activity (%) remaining in test
samples versus the control (no sample added).
2.7. cBLG-Immunized Mice. Pathogen-free female BALB/c
mice (4 weeks of age, 𝑛 = 3) were purchased from Japan SLC
(Shizuoka, Japan) and housed under temperature- and light-
controlled conditions. Mice were fed a standard diet (MF,
Oriental Yeast Co., Ltd., Tokyo, Japan) and sterile water ad
libitum. After a 1-week preliminary acclimatization period,
mice were sensitized with 100𝜇g of cBLG emulsified with
0.1mL of complete Freund’s adjuvant (Difco Laboratories,
Detroit, MI, USA) and injected intraperitoneally. At 2 and
4 weeks after the first sensitization, mice were boosted with
100 𝜇g of cBLG emulsified with 0.1mL of incomplete Freund’s
adjuvant (Difco Laboratories). All experimental procedures
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Figure 2: Secretion of rBLG by NZ9000. Two rNZ9000 strains were cultured with (+) or without (−) 10 ng/mL of nisin. Protein extracts
from cells (a) or culture supernatants (b) were analyzed by Western blotting with a 6x His-tag Ab.White and black arrowheads indicate the
secretory rBLG precursor (pre-rBLG, 27 kDa) and the secretory form of rBLG (24.3 kDa), respectively.
were conducted in accordance with the Regulations for
Animal Experimentation of Shinshu University.
2.8. Immunoreactivity Assay. To investigate whether rBLG
is immunoreactive, splenocytes were isolated from cBLG-
immunized mice and the level of interleukin- (IL-) 13 mRNA
expression was measured using real-time quantitative PCR
(qPCR) following stimulation with purified rBLG. Spleno-
cytes were prepared using standard methods [15, 16] and
then cultured at a final concentration of 1 × 107 cells/well
(total volume of 2mL per well). Splenocytes were stimulated
with 50 or 100 𝜇g/mL of cBLG or purified rBLG. After
72 h of incubation, cells were harvested and IL-13 mRNA
expression was assessed using qPCR as previously described
[16]. Fluorescent qPCR was performed with SYBR Premix
Ex Taq (TaKaRa Bio Inc., Tokyo, Japan) and IL-13-specific
primers, with each reaction containing 5 ng of cDNA in a
total volume of 25𝜇L.The 𝛽-actin-specific and IL-13-specific
primers were purchased from TaKaRa Bio Inc. The PCR
cycling conditions were 10 s at 95∘C followed by 45 cycles of
5 s at 95∘C and 30 sec at 60∘C. As a control, poly (A)+ RNA
samples were used as templates to check for the presence
of contaminating genomic DNA. Reaction sensitivity and
amplification of contaminant products (e.g., extension of self-
annealed primers) were evaluated by amplifying serial dilu-
tions of the cDNA template. For cross-sample comparisons
of results obtained using various treatments, cytokinemRNA
levels were first normalized to 𝛽-actin mRNA levels. Results
are presented as the mean and SD of three independent
experiments.
2.9. Statistical Analysis. ANOVA and post hoc tests were
performed using the ystat2004.xls statistical software package
(Igakutosho Shuppan, Tokyo, Japan). One-way ANOVAwith
the post hoc Dunnett test or Student-Newman-Keuls test was
used to determine the significance of differences in DPP-
IV inhibitory assay and immunoreactivity assay, respectively.
Differences were considered significant at 𝑃 < 0.05.
3. Results and Discussion
3.1. Construction of the rBLG-Secreting NZ9000 Strain.
Genetically engineered LAB have recently emerged as suit-
able vehicles for the delivery of therapeutic proteins (e.g.,
antigens of pathogenic bacteria, allergen, and immunomod-
ulators such as cytokines) to the intestinal mucosa [17]. Many
heterologous gene expression systems for LAB have been
developed [18–20]. The nisin-controlled gene expression
(NICE) system, which utilizes a nisin-inducible promoter to
express downstream genes [21], is one of the most efficient
expression systems and is commonly used with L. lactis and
other LAB [22, 23].
In the current study, we constructed the secretion plasmid
pNZ8148#2:SEC (Figure 1(a)), which is a modified form of
pNZ8148, the standard plasmid used in the NICE system.
The pNZ8148#2:SEC plasmid contains sequences encoding
the nisin-inducible promoter (𝑃nis), usp45 signal peptide
(SP
𝑢𝑠𝑝45
), 6x His-tag, a Factor Xa recognition site, and
a terminator. This plasmid was cloned from the unmu-
tated BLG gene (Figure 1(b)) and then introduced into
NZ9000, resulting in the generation of NZ9000:SEC-BLG.
The NZ9000:SEC-BLG strain was induced with nisin, and
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Figure 3: Determination of the optimal nisin concentration for secretion of rBLG by NZ9000. (a) Strain NZ9000:SEC-BLG was cultured
with various concentrations of nisin (0 to 500 ng/mL). After 3 h of incubation, the OD
600
of each sample was measured. The mean and SD
from three independent experiments are shown. (b) Protein extracts from cells (CELL, above) or culture supernatants (SUP, below) were
analyzed by Western blotting with a 6x His-tag Ab. Representative images from three independent experiments are shown.White and black
arrowheads indicate the secretory rBLG precursor (pre-rBLG, 27 kDa) and the secretory form of rBLG (24.3 kDa), respectively.
rBLG expression and secretion were validated by Western
blotting with an anti-6x His-tag Ab. A strong secretory rBLG
precursor signal (pre-rBLG, 27 kDa) and a weak band repre-
senting the secretory form of rBLG (24.3 kDa) were observed
on Western blotting of the cell extract of nisin-induced
NZ9000:SEC-BLG (Figure 2(a)). Moreover, a single band
corresponding to rBLG was detected in the culture super-
natant of nisin-induced NZ9000:SEC-BLG (Figure 2(b)). No
signalwas detected in analyses of protein extracts of the nisin-
induced NZ9000:SEC-VC and noninduced NZ9000 strains
(Figure 2). We clearly demonstrated that NZ9000:SEC-BLG
intracellular expression of pre-rBLG is dependent on nisin
stimulation and that this protein is subsequently secreted by
the cell’s secretory machinery [18].
3.2. Optimal Conditions for rBLG Secretion by NZ9000.
Previous studies suggested that the amount of a protein
expressed in an engineered LAB may be increased in a nisin-
concentration-dependent manner using the NICE system
[24]. We addressed this possibility in our previous research
[13, 14]. In this study, we show that rBLG expression and
secretion are nisin-concentration dependent (Figure 3(b)).
Inhibition of bacterial proliferation (Figure 3(a)) and an
increase in the intensity of a band corresponding to pre-
rBLG in the culture supernatant (Figure 3(b)) were observed
in NZ9000:SEC-BLG cultured with nisin at concentrations
greater than 16 ng/mL.
Nisin, a typical type-A(I) lantibiotic produced by some
L. lactis strains, exhibits bactericidal activity against a wide
range of Gram-positive bacteria [25]. The mechanism of
nisin’s antimicrobial action is thought to involve (i) inhibition
of cell wall biosynthesis by scavenging of the peptidoglycan
precursor lipid II and (ii) lysis of the cell membrane by
the formation of pores [26]. Our observations suggest that
although the level of rBLG production by NZ9000:SEC-BLG
increases in a nisin-concentration-dependent manner, expo-
sure to high nisin concentrations (i.e., >16 ng/mL) results
Imidazole (mM)
Wash Elution
Cr
ud
e l
ys
at
e
Fl
ow
-th
ro
ug
h
20 31 63 125 250 500
Figure 4: Purification of rBLG secreted by NZ9000. Expression
of rBLG by NZ9000 was induced in a 4 L large-scale culture. The
cell extract (crude lysate) was prepared as described in Section 2
and then passed through a HisTrap HP column (flow-through). The
column was washed to remove nonadsorbed protein (wash) and
then eluted (elution) with wash buffer containing 20mM imidazole
and elution buffers containing 31 to 500mM imidazole. All fractions
were analyzed by Western blotting with a 6x His-tag Ab.White and
black arrowheads indicate the secretory rBLG precursor (pre-rBLG,
27 kDa) and the secretory form of rBLG (24.3 kDa), respectively.
in significant cell damage. Based on these results, 15 ng/mL
was determined to be the optimal nisin concentration for
maximizing rBLG secretion.
3.3. Purification of rBLG Produced by NZ9000. Expression
of rBLG by strain NZ9000:SEC-BLG was induced in a 4 L
large-scale culture, after which the protein was isolated and
purified. The cellular crude lysate was passed through a
HisTrap HP column and the flow-through was collected.The
columnwas washed to remove nonadsorbed proteins and the
adsorbed proteins were eluted with various concentrations
of imidazole (20 to 500mM). To confirm the purification of
rBLG, all fractions were analyzed by Western blotting with
an anti-6x His-tag Ab (Figure 4). Bands corresponding to
pre-rBLG and/or rBLG were observed in each of the eluted
fractions. Pre-rBLG and rBLG were particularly abundant
in the fractions eluted with 63 and 125mM imidazole.
However, highly purified rBLG samples (i.e., fractions eluted
6 BioMed Research International
105
100
95
90
85
80
Control 1 10 100
D
PP
-I
V
 ac
tiv
ity
 (%
)
∗
∗∗
∗∗
cBLG (𝜇g/mL)
(a)
105
100
95
90
85
80
D
PP
-I
V
 ac
tiv
ity
 (%
) ∗∗
∗∗
Control cBLG rBLG
(b)
Figure 5: Inhibition ofDPP-IV activity by trypsin-digested rBLG.Various concentrations of trypsin-digested cBLG (a) or trypsin hydrolysates
of 50 𝜇g/mL of either cBLG or purified rBLG (b) were evaluated for inhibitory activity against DPP-IV using a DPP-IV Drug Discovery Kit.
Concentrations indicated are the protein concentrations before trypsin treatment. Data are expressed as percent activity remaining in test
samples versus that in the control (no sample added). Black, dotted white, and dotted black bars indicate control, cBLG, and purified rBLG
(rBLG), respectively. Values represent means and error bars indicate SD (𝑛 = 3). ∗𝑃 < 0.05; ∗∗𝑃 < 0.01 versus control.
with 250 and 500mM imidazole) were used in subsequent
experiments.
3.4. Inhibition of DPP-IV Activity by Trypsin-Digested rBLG.
Trypsin-digested cBLG inhibited the activity of the DPP-IV
enzyme in a concentration-dependent manner (Figure 5(a)).
The inhibitory activity of trypsin-digested rBLG against DPP-
IVwas similar to that of cBLG (Figure 5(b)). Uchida et al. also
showed that DPP-IV inhibitory activity of trypsin-digested
BLG was exerted in a concentration-dependent fashion, and
IC
50
value was 210 𝜇M [8]. Thus, highly concentrated tryptic
hydrolysate of rBLG may efficiently inhibit DPP-IV activity.
Other studies have shown that some peptides produced by
trypsin digestion of BLG inhibit DPP-IV activity [6, 8].
Particularly, the pentapeptide IPAVF exhibits the strongest
inhibitory activity [6]. The strong inhibition of DPP-IV
activity observed with trypsin-digested rBLG in this study
was probably because of the involvement of these peptides
within the rBLG.
3.5. Immunoreactivity of rBLG. Vaccines using genetically
modified LAB as mucosal antigen delivery vehicles have
been tested in mouse models of allergies to house dust
mites [27–29], eggs [30], birch pollen [31], Japanese cedar
pollen [32], and cow’s milk [33]. These studies demon-
strated suppression of the allergic response by LAB vaccines
through induction of immune response by T-helper (Th)1
or regulatory T cells. Indeed, Adel-Patient et al. showed
that oral pretreatment with a BLG-producing L. lactis strain
prevents Th2-type immune responses through a reduction
in BLG-specific IgE production and the upregulation of
specificTh1-type IgG2a and fecal IgA production [34].There-
fore, we also investigated the immunoreactivity of L. lactis-
produced rBLG using a simple in vitro assay system that
we previously developed [13, 14]. In this study, IL-13 mRNA
expression was significantly enhanced in a dose-dependent
manner in splenocytes stimulated with cBLG as compared
with medium-stimulated control cells (Supplemental Figure
1 available online at http://dx.doi.org/10.1155/2014/393598).
Similar results were observed with cells stimulated with
purified rBLG (Supplemental Figure 1).These results indicate
that rBLG demonstrates immunoreactivity as strong as that
of cBLG. Hence, NZ9000:SEC-BLG may be useful not only
in managing T2D but also in therapies to treat or prevent
allergies to cow’s milk.
4. Conclusions
We developed a L. lactis strain (NZ9000 : SEC-BLG) that
efficiently secretes rBLG. The rBLG produced by this
strain demonstrates both strong allergenicity and inhibi-
tion of DPP-IV activity following trypsin digestion. The
NZ9000:SEC-BLG strain may prove useful in therapies for
treating T2D and allergies to cow’s milk.
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